• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

九个国际司法管辖区的卵巢癌诊断途径和时间间隔;国际癌症基准伙伴关系(ICBP)的研究结果。

Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).

机构信息

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.

Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.

出版信息

Br J Cancer. 2022 Sep;127(5):844-854. doi: 10.1038/s41416-022-01844-0. Epub 2022 May 26.

DOI:10.1038/s41416-022-01844-0
PMID:35618787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9427750/
Abstract

BACKGROUND

International Cancer Benchmarking Partnership Module 4 reports the first international comparison of ovarian cancer (OC) diagnosis routes and intervals (symptom onset to treatment start), which may inform previously reported variations in survival and stage.

METHODS

Data were collated from 1110 newly diagnosed OC patients aged >40 surveyed between 2013 and 2015 across five countries (51-272 per jurisdiction), their primary-care physicians (PCPs) and cancer treatment specialists, supplement by treatment records or clinical databases. Diagnosis routes and time interval differences using quantile regression with reference to Denmark (largest survey response) were calculated.

RESULTS

There were no significant jurisdictional differences in the proportion diagnosed with symptoms on the Goff Symptom Index (53%; P = 0.179) or National Institute for Health and Care Excellence NG12 guidelines (62%; P = 0.946). Though the main diagnosis route consistently involved primary-care presentation (63-86%; P = 0.068), onward urgent referral rates varied significantly (29-79%; P < 0.001). In most jurisdictions, diagnostic intervals were generally shorter and other intervals, in particular, treatment longer compared to Denmark.

CONCLUSION

This study highlights key intervals in the diagnostic pathway where improvements could be made. It provides the opportunity to consider the systems and approaches across different jurisdictions that might allow for more timely ovarian cancer diagnosis and treatment.

摘要

背景

国际癌症基准合作组织模块 4 报告了首次对卵巢癌(OC)诊断途径和间隔(症状出现至治疗开始)的国际比较,这可能有助于解释先前报告的生存率和分期差异。

方法

从 2013 年至 2015 年在五个国家(每个司法管辖区 51-272 例)对 1110 例新诊断的 OC 患者进行了调查,收集了这些患者及其初级保健医生(PCP)和癌症治疗专家的数据,并通过治疗记录或临床数据库进行了补充。使用丹麦(调查回复最大的国家)作为参考,使用分位数回归计算了诊断途径和时间间隔的差异。

结果

在 Goff 症状指数(53%;P=0.179)或国家卫生与保健卓越研究所 NG12 指南(62%;P=0.946)上诊断出症状的比例在司法管辖区之间没有显著差异。尽管主要的诊断途径始终涉及初级保健就诊(63-86%;P=0.068),但紧急转介率差异显著(29-79%;P<0.001)。在大多数司法管辖区,诊断间隔通常较短,而其他间隔,特别是治疗间隔,与丹麦相比更长。

结论

本研究强调了诊断途径中可以改进的关键间隔。它为考虑不同司法管辖区的系统和方法提供了机会,这些方法可能有助于更及时地进行卵巢癌诊断和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da8f/9427750/249c29920cde/41416_2022_1844_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da8f/9427750/6509f8892fdb/41416_2022_1844_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da8f/9427750/249c29920cde/41416_2022_1844_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da8f/9427750/6509f8892fdb/41416_2022_1844_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da8f/9427750/249c29920cde/41416_2022_1844_Fig2_HTML.jpg

相似文献

1
Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).九个国际司法管辖区的卵巢癌诊断途径和时间间隔;国际癌症基准伙伴关系(ICBP)的研究结果。
Br J Cancer. 2022 Sep;127(5):844-854. doi: 10.1038/s41416-022-01844-0. Epub 2022 May 26.
2
Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).10 个司法管辖区肺癌诊断的时间间隔和途径:国际癌症基准伙伴关系(ICBP)的横断面研究结果。
BMJ Open. 2019 Nov 27;9(11):e025895. doi: 10.1136/bmjopen-2018-025895.
3
Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP).10个国际司法管辖区结直肠癌患者的诊断途径和时间间隔;来自国际癌症基准伙伴关系(ICBP)的横断面研究结果。
BMJ Open. 2018 Nov 27;8(11):e023870. doi: 10.1136/bmjopen-2018-023870.
4
An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation.作为国际癌症基准伙伴关系的一部分,对10个国际司法管辖区的癌症诊断途径进行调查:调查的开展与实施。
BMJ Open. 2016 Jul 25;6(7):e009641. doi: 10.1136/bmjopen-2015-009641.
5
Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data.10 个国际癌症基准合作组织(ICBP)司法管辖区的乳腺癌诊断途径:基于问卷调查和登记数据的国际比较队列研究。
BMJ Open. 2022 Dec 15;12(12):e059669. doi: 10.1136/bmjopen-2021-059669.
6
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.急诊入院后 30 天内诊断癌症(急诊就诊)的风险因素和预后意义:国际癌症基准合作组织(ICBP)基于人群的研究。
Lancet Oncol. 2022 May;23(5):587-600. doi: 10.1016/S1470-2045(22)00127-9. Epub 2022 Apr 6.
7
Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey.解释国际癌症基准伙伴关系中11个辖区间癌症生存率差异:一项初级保健病例调查
BMJ Open. 2015 May 27;5(5):e007212. doi: 10.1136/bmjopen-2014-007212.
8
Advanced-stage cancer and time to diagnosis: An International Cancer Benchmarking Partnership (ICBP) cross-sectional study.晚期癌症与诊断时间:国际癌症标杆合作组织(ICBP)的一项横断面研究。
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13100. doi: 10.1111/ecc.13100. Epub 2019 May 22.
9
Variation in suspected cancer referral pathways in primary care: comparative analysis across the International Benchmarking Cancer Partnership.初级保健中疑似癌症转诊途径的差异:国际基准合作的比较分析。
Br J Gen Pract. 2023 Jan 26;73(727):e88-e94. doi: 10.3399/BJGP.2022.0110. Print 2023 Feb.
10
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.食管癌、胃癌、结肠癌、直肠癌、肝癌、胰腺癌、肺癌和卵巢癌患者化疗的应用:一项基于国际癌症基准伙伴关系(ICBP)人群的研究。
Lancet Oncol. 2024 Mar;25(3):338-351. doi: 10.1016/S1470-2045(24)00031-7.

引用本文的文献

1
Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population.利用血清脂质组学结合蛋白质生物标志物和机器学习对有症状人群进行卵巢癌早期检测。
Cancer Res Commun. 2025 Sep 1;5(9):1516-1529. doi: 10.1158/2767-9764.CRC-25-0140.
2
Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis.基于免疫疗法的卵巢癌治疗的全球研究趋势:文献计量与可视化分析
J Multidiscip Healthc. 2025 Jul 25;18:4197-4217. doi: 10.2147/JMDH.S526280. eCollection 2025.
3
Low Serum Cholinesterase Levels Predict Poor Prognosis in Patients with Ovarian Cancer.

本文引用的文献

1
Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes.肺癌、结直肠癌、前列腺癌和卵巢癌的分期、生存率及延误情况:不同诊断途径的比较
Br J Gen Pract. 2007 Mar;57(536):212-9.
低血清胆碱酯酶水平预示卵巢癌患者预后不良。
Int J Gen Med. 2025 Feb 25;18:1023-1033. doi: 10.2147/IJGM.S509718. eCollection 2025.
4
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS.评估卵巢癌CA-125临床前可检测阶段、体内肿瘤倍增时间及早期检测窗口:英国卵巢癌筛查协作组的探索性分析
EBioMedicine. 2025 Feb;112:105554. doi: 10.1016/j.ebiom.2024.105554. Epub 2025 Jan 13.
5
LncRNA DNM1P35 sponges hsa-mir-326 to promote ovarian cancer progression.长链非编码RNA DNM1P35通过吸附hsa-mir-326促进卵巢癌进展。
Sci Rep. 2024 Dec 28;14(1):31502. doi: 10.1038/s41598-024-83170-4.
6
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.欧洲卵巢癌回顾性研究(O'CaRE):根据进展风险因素数量得出的一线治疗结果
Future Oncol. 2024 Dec;20(40):3409-3419. doi: 10.1080/14796694.2024.2402217. Epub 2024 Oct 24.
7
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).临床前期浸润性上皮性卵巢癌的卵巢癌症状 - 嵌套在英国卵巢癌筛查协作试验(UKCTOCS)中的探索性分析。
Gynecol Oncol. 2023 Dec;179:123-130. doi: 10.1016/j.ygyno.2023.11.005. Epub 2023 Nov 18.
8
Pathways to diagnosis of endometrial and ovarian cancer in the 45 and Up Study cohort.45 and Up 研究队列中子宫内膜癌和卵巢癌的诊断途径。
Cancer Causes Control. 2023 Jan;34(1):47-58. doi: 10.1007/s10552-022-01634-2. Epub 2022 Oct 9.